Search details
1.
Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL.
J Infect Dis
; 2024 Mar 04.
Article
in English
| MEDLINE | ID: mdl-38437622
2.
2024 Update: Advances in the risk stratification and management of large B-cell lymphoma.
Am J Hematol
; 98(11): 1791-1805, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37647158
3.
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(3): 285-308, 2022 03.
Article
in English
| MEDLINE | ID: mdl-35276674
4.
Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.
Br J Haematol
; 195(2): 201-209, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34341990
5.
Brentuximab vedotin in the treatment of CD30+ PTCL.
Blood
; 134(26): 2339-2345, 2019 12 26.
Article
in English
| MEDLINE | ID: mdl-31697814
6.
A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening.
Blood
; 134(2): 171-185, 2019 07 11.
Article
in English
| MEDLINE | ID: mdl-31151983
7.
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
Haematologica
; 106(6): 1705-1713, 2021 06 01.
Article
in English
| MEDLINE | ID: mdl-32414850
8.
Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival.
Eur J Haematol
; 107(3): 301-310, 2021 Sep.
Article
in English
| MEDLINE | ID: mdl-33973276
9.
2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management.
Am J Hematol
; 96(5): 617-629, 2021 05 01.
Article
in English
| MEDLINE | ID: mdl-33661537
10.
Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era.
Am J Hematol
; 96(11): 1374-1384, 2021 11 01.
Article
in English
| MEDLINE | ID: mdl-34324220
11.
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
Cancer
; 126(2): 293-303, 2020 01 15.
Article
in English
| MEDLINE | ID: mdl-31568564
12.
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy.
Br J Haematol
; 191(1): 44-51, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32430944
13.
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma.
Oncologist
; 25(6): e993-e997, 2020 06.
Article
in English
| MEDLINE | ID: mdl-32275786
14.
Is it prime time for T-cell lymphoma?
Blood
; 141(18): 2161-2163, 2023 05 04.
Article
in English
| MEDLINE | ID: mdl-37140951
15.
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021.
J Natl Compr Canc Netw
; 18(11): 1460-1467, 2020 11 02.
Article
in English
| MEDLINE | ID: mdl-33152703
16.
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.
J Natl Compr Canc Netw
; 18(5): 522-536, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32380458
17.
Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs.
Oncologist
; 24(11): e1236-e1250, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31346132
18.
AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 17(2): 171-189, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30787130
19.
Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 16(8): 986-1017, 2018 08.
Article
in English
| MEDLINE | ID: mdl-30099375
20.
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.
J Natl Compr Canc Netw
; 16(2): 123-135, 2018 Feb.
Article
in English
| MEDLINE | ID: mdl-29439173